2018 Q3 Sentiment Medicinova Inc (NASDAQ:MNOV)

Sentiment for Medicinova Inc (NASDAQ:MNOV)

Medicinova Inc (NASDAQ:MNOV) institutional sentiment increased to 1.15 in 2018 Q3. Its up 0.11, from 1.04 in 2018Q2. The ratio is better, as 23 funds increased or started new stock positions, while 20 trimmed and sold stock positions in Medicinova Inc. The funds in our partner’s database reported: 8.63 million shares, down from 8.79 million shares in 2018Q2. Also, the number of funds holding Medicinova Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 10 Reduced: 10 Increased: 19 New Position: 4.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company has market cap of $396.20 million. The companyÂ’s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. It currently has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

The stock decreased 2.47% or $0.24 during the last trading session, reaching $9.46. About 33,639 shares traded. MediciNova, Inc. (NASDAQ:MNOV) has risen 28.16% since January 14, 2018 and is uptrending. It has outperformed by 28.16% the S&P500.

Analysts await MediciNova, Inc. (NASDAQ:MNOV) to report earnings on February, 12.

Wexford Capital Lp holds 0.1% of its portfolio in MediciNova, Inc. for 125,000 shares. Bridgeway Capital Management Inc owns 132,710 shares or 0.02% of their US portfolio. Moreover, Alps Advisors Inc has 0.01% invested in the company for 74,109 shares. The New York-based Alliancebernstein L.P. has invested 0% in the stock. American International Group Inc, a New York-based fund reported 26,444 shares.

More notable recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: Bioworld.com which released: “Medicinova shares climb on positive ALS trial analyses – BioWorld Online” on July 10, 2018, also Finance.Yahoo.com with their article: “The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study – Yahoo! Finance News” published on January 09, 2019, Globenewswire.com published: “MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo – GlobeNewswire” on March 12, 2018. More interesting news about MediciNova, Inc. (NASDAQ:MNOV) were released by: Seekingalpha.com and their article: “MediciNova: CEO Faces Undisclosed Illegal Kickback Lawsuit, Failed Science, Perplexing Related Party Transactions, -84% Downside – Seeking Alpha” published on March 03, 2016 as well as Seekingalpha.com‘s news article titled: “Early ALS patients better responders to MediciNova’s MN-166 – Seeking Alpha” with publication date: July 10, 2018.

MediciNova, Inc. (NASDAQ:MNOV) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.